doi: 10.3389/fcimb.2026.1752304 Received 23 November 2025 Revised 12 January 2026 Accepted 31 January 2026 Published 19 February 2026 Volume 16 - 2026 Edited by Teclegiorgis Gebremariam, Lundquist Institute for Biomedical Innovation, United States Reviewed by Fatemeh Ahangarkani, 4cyte Pathology, Australia Sanam Dolati, Lundquist Institute for Biomedical Innovation, United States Updates Copyright 2026 Wu, Jiang, Wang, Chen, Chen and Da
GLP-1 Receptor Agonists: Mechanisms of Action and Class Overview Mechanism of Action: GLP-1 receptor agonists (incretin mimetics) work by mimicking the action of endogenous GLP-1, a gut hormone (incretin) that is released in response to nutrient intake
Tirzepatide tends to be the better fit when: the goal is more significant weight loss (15 percent or more of body weight), the patient has type 2 diabetes with A1C above target on prior therapies, prior single-pathway GLP-1 use produced limited results, or the patient tolerated GLP-1s reasonably well and wants a stronger next step
Finally, recent clinical trials for obesity are exploring very high doses of semaglutide, with regimens of up to 50 mg/week demonstrating additional efficacy 8688
but Mandie is always happy to answer